The oral pipeline for psoriasis

Quote:

---

While there isn’t much public information on oral psoriasis drugs in the pipeline, the National Psoriasis Foundation lists about 10 orals for psoriasis in phase 2 or phase 3 trials.

They are:
Prurisol (Cellceutix) is a small molecule that acts through immune modulation and PRINS (psoriasis associated RNA induced by stress) reduction and which is over-expressed in psoriasis. The drug has completed a phase 2 FDA trial under the U.S. Food and Drug Administration’s 505(b)(2) pathway. The placebo-controlled, randomized, double-blind trial tested efficacy and safety of three separate, twice-daily, dosing regimens: 50 milligram (mg) (50mg QD), 100mg (50mg BD), and 200mg (100mg BD). At the end of the 84-day treatment period, 35% of patients in the 200-mg arm demonstrated clinically significant improvements compared with 16.7% in the placebo only group, according to the recent press release. The primary endpoint was the percent of patients who achieved at least a two-point improvement from baseline on the IGA 5-point scale as measured by visual inspection of patient lesions at the end of treatment period. Further analysis showed the greatest efficacy was in patients with moderate disease (IGA 3), according to the company. Only one Serious Adverse Event was reported in the 50-mg arm. Additional Adverse Events were reported similarly across each dosing arm and the placebo arm, the company notes.

---

http://dermatologytimes.modernmedicine.com/de...l-pipeline

Nice to see P getting the first mention. #2 (XP23829) and #10 (TP-43742) have deals already. None of the drugs are currently in Phase 3, so P might reach market first due to its 505(b)(2) pathway.